Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Liye DaiJie XuHongyi YanZimo ChenYue-Song PanXia MengHao LiYong-Jun WangPublished in: Stroke (2021)
Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score. Our study suggests that CYP2C19 genotypes and clinical risk factors can be integrated by ABCD-GENE score to estimate the efficacy of clopidogrel-aspirin therapy.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- chronic kidney disease
- body mass index
- percutaneous coronary intervention
- risk factors
- low dose
- genome wide
- type diabetes
- cerebral ischemia
- cardiovascular disease
- copy number
- atrial fibrillation
- cardiovascular events
- end stage renal disease
- randomized controlled trial
- high throughput
- study protocol
- physical activity
- ischemia reperfusion injury
- weight gain
- phase ii
- insulin resistance
- brain injury
- transcription factor